Vertex Pharmaceuticals Incorporated (VRTX)
Nasdaq · Healthcare · Biotechnology
$503.50−0.24%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $128B
- P/E (trailing)
- 29.3
- Forward P/E
- 25.0
- 52-week range
- $400.74 – $560.25
- 52-week change
- +25.27%
- EPS (trailing)
- $17.17
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $12.0B (+8.90%)
- Net income
- $4.0B
- Operating margin
- 34.8%
- Diluted EPS
- $15.32
- Free cash flow
- $3.2B
From the company’s annual report on SEC EDGAR.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
Headquarters: Boston, United States · 6,400 employees · vrtx.com